
Intellia Therapeutics Secures FDA Clearance to Resume MAGNITUDE Phase 3 Trial in ATTR-CM
Intellia Therapeutics Reports FDA Clearance to Resume MAGNITUDE Phase 3 Study in ATTR-CM Following Removal of Clinical Hold Intellia Therapeutics has cleared a significant regulatory hurdle in its effort to…











